Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

0.5500 +0.0400 (+7.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Analyst Ratings for Verrica Pharmaceuticals
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Verrica Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Recap: Verrica Pharmaceuticals Q1 Earnings
Verrica Pharmaceuticals (NASDAQ:VRCA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance 
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval
Monday, the FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
Via Benzinga
$1M Bet On Verrica Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday
The company's shares dropped because it will require financing to help launch its first marketed product. 
Via The Motley Fool
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
FDA Approves Verrica Pharma's Ycanth: First Treatment Of Molluscum Contagiosum Impacting 6M People In US
The FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients  
Via Benzinga
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers. 
Via InvestorPlace
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023
Via Benzinga
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.